NCT02285816View on ClinicalTrials.gov

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

September 19, 2019

Study Completion Date

December 31, 2025

Conditions
Advanced/Metastatic Solid Tumours
Interventions
BIOLOGICAL

MG1MA3

MG1MA3: Boosting component of Oncolytic Vaccine

BIOLOGICAL

AdMA3

AdMA3: Priming component of Oncolytic Vaccine

Trial Locations (4)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Ottawa Hospital Research Institute

OTHER

lead

Canadian Cancer Trials Group

NETWORK